Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-27
2010-10-12
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C435S208000
Reexamination Certificate
active
07812033
ABSTRACT:
Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compoiunds are effective to enhance glucocerebrosidase activity.
REFERENCES:
patent: 4639436 (1987-01-01), Junge et al.
patent: 5030628 (1991-07-01), Partis et al.
patent: 5030638 (1991-07-01), Partis et al.
patent: 5043273 (1991-08-01), Scudder et al.
patent: 5051407 (1991-09-01), Boshegan et al.
patent: 5192772 (1993-03-01), Yoshikuni et al.
patent: 5250545 (1993-10-01), Tsuroka et al.
patent: 5292750 (1994-03-01), Yoshikuni et al.
patent: 5399567 (1995-03-01), Platt et al.
patent: 5504078 (1996-04-01), Ducep et al.
patent: 5561221 (1996-10-01), Yoshida et al.
patent: 5580884 (1996-12-01), Platt et al.
patent: 5596005 (1997-01-01), Wong et al.
patent: 5622972 (1997-04-01), Bryant et al.
patent: 5643888 (1997-07-01), Rorschneider
patent: 5656641 (1997-08-01), Platt et al.
patent: 5691306 (1997-11-01), Bergeron et al.
patent: 5786368 (1998-07-01), Platt et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5801185 (1998-09-01), Platt et al.
patent: 5844102 (1998-12-01), Sierks et al.
patent: 5863903 (1999-01-01), Lundgren et al.
patent: 5981494 (1999-11-01), Rademacher et al.
patent: 6177447 (2001-01-01), Aerts
patent: 6210666 (2001-04-01), Miyamura
patent: 6225325 (2001-05-01), Jacob
patent: 6274597 (2001-08-01), Fan et al.
patent: 6291657 (2001-09-01), Platt et al.
patent: 6465488 (2002-10-01), Butters et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6774135 (2004-08-01), Fan et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: 7174582 (2006-11-01), Fan et al.
patent: 7514453 (2009-04-01), Fan et al.
patent: 2001/0018090 (2001-08-01), Noda et al.
patent: 2001/0044453 (2001-11-01), Jacob et al.
patent: 2002/0006909 (2002-01-01), Perlmutter et al.
patent: 2002/0095135 (2002-07-01), Meeker et al.
patent: 2002/0115667 (2002-08-01), Walkley et al.
patent: 2004/0242539 (2004-12-01), Fan et al.
patent: 2278507 (1998-07-01), None
patent: 61-280472 (1985-06-01), None
patent: WO 87/03903 (1987-07-01), None
patent: WO 92/00277 (1993-04-01), None
patent: WO 95/19172 (1995-07-01), None
patent: WO 99/24401 (1999-05-01), None
patent: WO 99/40435 (1999-08-01), None
patent: WO 99/62517 (1999-12-01), None
patent: WO 00/29556 (2000-05-01), None
patent: WO 00/32175 (2000-06-01), None
patent: WO 00/33843 (2000-06-01), None
patent: WO 00/56334 (2000-09-01), None
patent: WO 00/62799 (2000-10-01), None
patent: WO 01/02862 (2001-01-01), None
patent: WO 01/07078 (2001-02-01), None
patent: WO 01/10429 (2001-02-01), None
patent: WO 01/21652 (2001-03-01), None
patent: WO 94/26714 (2001-09-01), None
patent: WO 02/28348 (2002-04-01), None
Tropak and Mahuran, “Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells”, FEBS Journal 274: 4951-4961 (2007).
Naoki Asano, et al., “In Vitro inhibition and intracellular enhancement of lysosmal α-galactosidase A by deoxygalactonojirimycin and its derivatives,” Eur. J. Biochem 2000; vol. 267, pp. 4179-4186.
Naoki Asano et al., “Specific alpha galactosidase inhibitors, N-methylcalystegines-structure/activity relationships of calystegines fromLycium chinense,” Eur. J. Biochem., vol. 248: 296-303, 1997.
Naoki Asano et al., “Homojirimycin isomers and glycosides fromAglaonema treubii,” J. Nat. Prod. 1997; vol. 60, p. 98.
Naoki Asano et al., “Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases,” J. Med. Chem. 1994; vol. 37, pp. 3701.
Bernotas et al., “Synthesis of (+)-1, 5-dideoxy-1,5-imino-D-galactitol, a potent alpha galactosidase inhibitor,” Carbohydrate Res., vol. 167: 306-311, Sep. 1987.
C. Randall Brown, et al., “Chemical chaperones correct the mutant phenotype of the F508 cystic fibrosis transmembrane conductance regulator protein,” Cell Stress & Chaperones 1996; vol. 1 No. 2, pp. 117-125.
Jon A. Burrows et al., “Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency,” Proc. Natl. Acad. Sci. U.S.A. 2000; vol. 97, No. 4, pp. 1796-1801.
M.P. Dale et al., “Reversible inhibitors of beta-glucosidase,” Biochemistry 1985; vol. 24, pp. 3530-3539.
Jian-Qiang Fan, et al., “Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor,” Nature Medicine 1999; vol. 5, No. 1, pp. 112-115.
Barbara A. Foster, et al., “Pharmacological Rescue of mutant p53 conformation and function,” Science 1999; vol. 286, pp. 2507-2510.
Goldmann et al., “Biological activities of the nortropane alkaloid, calystegine B2, and analogs: structure function relationships,” J. Natl. Prod., vol. 59, pp. 1137-1142, 1996.
A. M Hurtley and A. Helenius, “Protein oligomerization in the endoplasmic reticulum,” Annu. Rev. Cell Biol. 1989; vol. 5, pp. 277-307.
Ishii et al., “Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease,” Biochem. Biophys. Res. Comm. 1993; 197(3):1585-89.
Galina Kuznetsov, et al., “Folding of secretory and membrane proteins,” New Engl. J. Med. 1998; vol. 339, No. 23, pp. 1688-1695.
Legler et al., “Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of alpha and beta-D-galactosidases,” Carbohydrate Research, vol. 155, pp. 119-129, Nov. 1986.
Tip W. Loo, et al., “Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators,” J. Biol. Chem. 1997; vol. 272, No. 2, pp. 709-712.
Jean-Pierre Morello, et al., “Pharmacological chaperones rescue cell-surface expression and functions of misfolded V2 vasopressin receptor mutants,” J. Clin. Invest. 2000; vol. 105, pp. 887-895.
Okumiya et al., Genetic Disease 1998; 2(1):76-82 (Japanese).
Okumiya et al., “Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease,” Biochem. Biophys. Res. Comm. 1997; vol. 214, pp. 1219-1224.
Okumiya e al., Biochem. Biophys. Res. Comm. 1995; 214(3): 1219-24.
Jean-Pierre Morello, et al., “Pharmacological chaperones: a new twist on receptor folding,” TiPS, 2000; vol. 21, pp. 466-469.
Ulla E. Petaja-Repo et al., “Ligands act as pharmacological chaperones and increase the efficiency of σ opioid receptor maturation,” The EMBO J. 2002; 21(7):1628-37.
F.M. Platt et al., “Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin,” Science 1997; vol. 276, pp. 428-431.
Frances M. Platt, et al., “N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis,” J. Biol. Chem. 1994; vol. 269, No. 11, pp. 8362-8365.
Frances M. Platt et al., “N-butyldeoxygalactonorjirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing,” J. Biol. Chem. 1994; vol. 269, No. 43, pp. 27108-27114.
Pobojewski et al., “Experimental drug reverses effects of Fabry disease,” The University Record (Univ. of Michigan), vol. 55, No. 34, p. 11, Jun. 2000.
Ronald C. Rubenstein, et al., In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylgutyrate in cystic fibrosis epithelial cells containing F508-CFTR,@ Pharmacologic Correction of F508-CFTR 1997; vol. 100, No. 10, pp. 2457-2464.
S
Asano Naoki
Fan Jian-Qiang
Ishii Satoshi
Baker & Botts LLP
Desai Anand U
Mount Sinai School of Medicine of New York University
LandOfFree
Method for increasing the activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing the activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing the activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224769